Newronika S.p.A. Secures €13.6M Series B Round to Revolutionize Brain-Computer Interfaces

Newronika S.p.A., a trailblazer in building brain-computer interfaces, is delighted to announce a successful funding round totalling €13,600,000. This strategic investment will fuel the company’s ongoing mission to restore brain and body functions using its groundbreaking technologies. By deeply decoding biosignals and translating this innovative approach into clinical practice, Newronika is revolutionizing patient care—ensuring that each individual receives precise stimulation at the right moment. This timing not only enhances treatment efficacy but also empowers patients to resume their daily activities and significantly improve their quality of life. As the spin-off company of two prestigious Italian institutions—Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and the University of Milan—Newronika has built a robust foundation based on rigorous research and clinical excellence. The newly raised capital will be directed towards accelerating product development and clinical trials, broadening the applications of its state-of-the-art brain devices, and expanding its multidisciplinary team of experts. This team, which brings together leading scientists in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies, remains at the forefront of innovative research. The infusion of funds will also enhance Newronika’s capacity to bridge the gap between laboratory discoveries and real-world healthcare solutions, thereby catalysing more personalized and effective treatments for neurological conditions. This funding milestone marks a pivotal advancement for Newronika S.p.A. as it continues to push the boundaries of neuroscience, inspiring further research and development to unlock new paradigms in health and wellness. The company looks forward to transforming these investments into transformative solutions that benefit patients globally.